Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics innovator developing PCR-based testing solutions through its patented Co-Primers™ technology. This page serves as the definitive source for verified company news and announcements, providing stakeholders with timely updates on developments impacting global healthcare diagnostics.
Investors and industry professionals will find curated press releases covering financial results, regulatory milestones, product launches, and strategic partnerships. Our aggregation includes updates on CODX's expanding test menu (including tuberculosis and respiratory disease diagnostics), manufacturing expansions, and progress toward decentralized testing solutions through the Co-Dx™ platform.
Key resources include earnings call transcripts, FDA clearance announcements, and analysis of emerging market initiatives like the CoSara Diagnostics joint venture in India. All content is organized chronologically demonstrate the company's trajectory while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis. Check regularly for updates on CODX's contributions to accessible, high-accuracy diagnostic testing worldwide.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation at the Medical Fair Brasil from May 3-6, 2022, in São Paulo. This international exhibition focuses on hospital and diagnostic supplies, attracting key healthcare professionals. Co-Dx will showcase its innovative molecular diagnostic technologies, including a new point-of-care rapid PCR diagnostics platform. The event offers an opportunity for Company representatives to connect directly with decision-makers in healthcare, enhancing product visibility and potential sales.
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company, announced that it will release its first quarter 2022 financial results on May 12, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. EDT to discuss these results with analysts and investors. Key management, including CEO Dwight Egan and CFO Brian Brown, will participate in the call. The call will be accessible via the company's website and will also be recorded for later viewing.
Co-Diagnostics, Inc. (Nasdaq: CODX) will host a booth at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal, from April 23-26, 2022. This congress will gather over 14,000 experts to discuss advances in clinical microbiology and infectious diseases. Co-Dx aims to engage potential international customers and showcase its upcoming rapid PCR diagnostics platform. The event will feature both onsite and online sessions, enhancing accessibility for attendees. For more details, visit ECCMID's official site.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, has received clearance from India's Central Drugs Standard Control Organization (CDSCO) to manufacture and sell the SARAQ™ Hepatitis C Viral Load Kit as an in vitro diagnostic. This new real-time PCR test is crucial for assessing responses to antiviral treatments for Hepatitis C, a disease causing nearly 300,000 deaths annually. With over 58 million people affected globally, the test represents an essential addition to CoSara's growing diagnostics portfolio, enhancing patient care in regions with high disease burdens.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported record full-year revenue of $97.9 million for 2021, up $23.3 million year-over-year, driven by sales of Logix Smart™ COVID-19 tests. Gross profit increased to $86.3 million, representing 88.2% of revenue. Net income was $36.7 million, down from $42.5 million in 2020. The company completed two strategic acquisitions and revealed a new at-home PCR diagnostic platform. Looking ahead, Q1 2022 revenue is projected between $21.0 million and $22.0 million.
Co-Diagnostics, Inc. (Nasdaq: CODX), a leader in molecular diagnostics, will present its YourTest™ PCR device at the 3rd Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference on March 23-24, 2022, in London, England. CEO Dwight Egan will discuss the device on March 23rd at 14:00 GMT. The conference focuses on advancements in diagnostic testing for medical viruses, particularly Covid-19. Co-Diagnostics aims to enhance global access to care and innovation in diagnostics.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the enhancement of its Scientific Advisory Board (SAB) by adding renowned experts in molecular diagnostics. New members include Dr. Carl Wittwer as Chairman, along with Dr. Karen C. Carroll, Dr. Noriko Kusukawa, and Dr. Anne Wyllie. CEO Dwight Egan emphasized that their expertise will aid the company's growth and market expansion. The press release highlights the impressive qualifications of the new advisors, with many holding significant patents and research contributions in the field.
Co-Diagnostics has authorized a $30 million share repurchase program to enhance shareholder value and demonstrate confidence in its financial health. CFO Brian Brown emphasized that this decision reflects the company's strong cash flow generation and strategic capital allocation in light of current share prices. The program is flexible, allowing management to decide on the timing and method of repurchases based on market conditions and capital needs.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its earnings release date for the fourth quarter and full year 2021 on March 24, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. EDT to discuss financial results with analysts and investors. Key management on the call includes CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. The company focuses on developing molecular diagnostics technology for various applications, including infectious diseases.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its premium sponsorship of the Molecular Med Tri-Con from February 21-23, 2022, in San Diego, CA. The company will present its new Eikon PCR Platform during the event, aimed at delivering affordable, rapid, and accurate PCR testing for at-home and point-of-care use. Currently, the products based on this platform are pending FDA review and are not available for sale. This conference, organized by the Cambridge Healthtech Institute, is a key event in precision medicine and diagnostics.
